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1078-5884/$36 ª 2011 Published by E
doi:10.1016/j.ejvs.2010.12.014Abstract Objective: To evaluate whether ligation of the saphenofemoral junction (SFL)
improves the results of endovenous laser ablation (EVLA) of the great saphenous vein (GSV)
in a 5-year randomised clinical trial (RCT).
Methods: Forty-three symptomatic patients (86 limbs) with bilateral incompetent GSVs were
randomised so that one limb underwent EVLA without SFL and the other limb underwent EVLA
with SFL. Eleven patients were lost to follow-up and two patients died, leaving 30 patients (60
limbs) for analysis. Duplex-confirmed groin varicose vein recurrence and venous clinical
severity score (VCSS) were investigated at 6, 12, 24 and 60 months after treatment.
Results: Five-year life table analysis showed freedom fromgroin varicose vein recurrence in 79% of
limbs (95%confidence interval (CI); 67e92%) in the EVLAwithout SFL group and in 65% of limbs (95%;
CI; 51e82) in the EVLA with SFL group (PZ 0.36). Groin varicose vein recurrence was due to neo-
vascularisation (0%), re-canalisation (9%) and incompetent tributaries in 14% in the EVLA without
SFL group, and to neo-vascularisation (33%), re-canalisation (0%) and incompetent tributaries
(0%) in theEVLAwithSFLgroup.TheVCSS improvedsignificantlyandwascomparable inbothgroups.
Conclusion: The rate of varicose vein recurrence was similar in both study groups. There was less
neo-vascularisation in the EVLA without SFL group, but more incompetent tributaries and early
re-canalisation at 5-year follow-up than in the EVLA with SFL group.
Registration number: ISRCTN60300873 (http://www.clinical-trials.com).
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. Disselhoff, Burgemeester s’Jacoblaan 56, 1401 BS Bussum, The Netherlands. Tel.: þ31 302953737.
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686 B.C.V.M. Disselhoff et al.Introduction were randomised using numbered and sealed envelopes soEndovenous laser ablation (EVLA) is used to treat varicose
veins due to reflux in the great saphenous vein (GSV) and is
usually performed without ligation of the saphenofemoral
junction (SFL).1 Critics of endovenous techniques in the
treatment of varicose veins dispute thewisdomof not ligating
the saphenofemoral junction (SFJ) because of failure of vein
occlusiondue to the largediameterof the saphenousvein, the
development of a deep vein thrombosis (DVT) or a pulmonary
embolism. In addition, groin tributaries may remain patent,
which might promote recurrence of varicose veins. Others
argue that avoiding surgical disruption of the SFJ, as occurs
during ligation, may actually reduce neo-vascularisation,
leading to a reduced rate of recurrence.2 According to van Rij
et al., neo-vascularisation is a major cause of duplex-
confirmed recurrence of reflux in the groin after adequate
surgery.3
A randomised clinical trial (RCT) was conducted to deter-
mine whether SFL improves the results of EVLA of the GSV. In
our initial report, we found no clear advantage for additional
SFL in terms of occlusion rate, venous clinical severity score
(VCSS)4 and duplex-confirmed recurrent varicose veins, at
2 years’ follow-up.5 However, there is a tendency that with
longer follow-up the incidence of duplex-confirmed neo-
vascularisation in the groin following EVLA without SFL is
reduced and may also result in lower recurrence rates.6,7
The aim of this study was to evaluate the 5-year results of
the single-centre RCT comparing EVLA of the GSV with and
without SFL in patients with primary bilateral varicose veins.
Patients and Methods
Data were collected in a single-centre RCT of consecutive
patients with primary bilateral varicose veins, referred to our
hospital between March 2003 and February 2005. The study
protocol was approved by the regional ethics committee of
the Mesos Medical Centre, Utrecht, The Netherlands.
A detailed description of the perioperative details and
assessments has been published in our initial report.5
Several important aspects of this study deserve mention
here. The inclusion criteria were patients with primary
symptomatic varicose veins, CEAP (Clinical, Etiologic,
Anatomic and Pathophysiologic) clinical class C2 venous
disease,8 informed written consent, age range 20e75 years
and GSV incompetence from the groin to below the knee,
defined as retrograde flow lasting longer than 0.5 s on
duplex ultrasound scanning (ATL 3500 HDI, ATL Ultrasound,
Bothell, WA, USA). Reflux was detected by applying com-
pression to the calf followed by sudden release, using rapid
inflation pneumatic cuffs (Hokanson, Bellevue, USA).
Tributaries at the SFL (external pudendal, superficial
epigastric and superficial circumflex iliac vein) and acces-
sory saphenous veins exhibiting bi-directional flow were
defined as incompetent. Reasons for exclusion were
previous venous surgery, a history of suspected or proven
DVT, CEAP clinical class C3e6 venous disease, deep venous
reflux, incompetence of the perforating veins below the
knee, reflux of the GSV just to the knee, duplication of
the GSV, withholding of patient consent and others (Fig. 1).
After patients had given written informed consent, theythat one limb underwent EVLA without SFL and the other
limb underwent EVLA with SFL.
The procedures were performed as day cases. All patients
underwent their assigned treatment. Thirty-five patients
(81%) preferred general or spinal anaesthesia over local
anaesthesia. One surgeon experienced in EVLA techniques
and varicose vein surgery performed all the procedures. The
EVLA procedure has been described elsewhere.5 In brief, the
GSV, 5 cm below the knee, was accessed under ultrasound
guidance and the tip of the laser fibre was positioned
0.5e1 cmbelowtheSFJ.Underultrasoundmonitoring, 250ml
of tumescent local anaesthetic was administered within the
fascial sheath of the GSV. For patients undergoing treatment
under spinal or general anaesthesia, 250 ml NaCl 0.9% was
infiltrated around the vein. Manual compression was applied
over the GSV, while 12-W intermittent (one pulse on, one
pulse off) or 14-Wcontinuous laser energywas delivered from
0.5 to 1 cm below the SFJ to the access site at a pullback rate
of 0.2 cm s1. High ligation was performed through a 4-cm
incision in the groin,with flush division of theGSVand division
of all tributaries beyond the second level of division. The
groin incision was closed with the tissue adhesive
Dermabond (Johnson & Johnson, NJ, USA). After the
procedure, a graduated, thigh-length compression stocking
(20e30 mmHg) was worn day and night for 1 week. Post-
operative pain was managed with aceclofenac, 100 mg twice
daily for 1 week. Patients were instructed to walk immedi-
ately after the procedure, and were encouraged to resume
normal activities and return to work as soon as possible.
At each visit, physicians assessed patients’ signs and
symptoms using the VCSS, and employed duplex ultrasound
imaging to assess the abolition of GSV reflux and the
presence of recurrent varicose veins. Abolition of GSV
reflux was demonstrated by its complete occlusion or
obliteration, and duplex-ultrasound-detected recurrent
varicose veins were classified in accordance with Stone-
bridge.9 At 6 weeks, residual varicosities and accessory
saphenous veins underwent sclerotherapy with Aethoxy-
sclerol 1% (Kreussler, Germany). These adjunctive proce-
dures were intended as part of the initial treatment
approach, with the intention of removing all varicosities.
The primary outcome measure was freedom from recurrent
varicose veins in the groin, as confirmed by duplex ultra-
sound, 5 years after treatment. Secondary outcomes were
abolition of reflux in the GSV, VCSS scores and freedom
from overall recurrent varicose veins. Follow-up at 6, 12,
24 and 60 months was complete for 86 limbs (100%), 82
limbs (95%), 78 limbs (91%) and 60 limbs (70%), respec-
tively. Two patients were lost to follow-up at 12 months
because of discomfort during duplex examination, two at
24 months because of pregnancy and nine at 5 years (five
did not attend, two died (myocardial infarction and
carcinoma), and two refused).
Statistical Analysis
We hypothesised that SFL would not improve the outcome of
EVLA. To our knowledge in 2003, there were no RCT data
available comparing different options for venous surgery
in the same patient with primary varicose veins. Hence,
a formal power calculation could not be performed. The
Assessed for eligibility 
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Figure 1 CONSORT flow chart. EVLA, endovenous laser ablation. SFL, saphenofemoral ligation.
Clinical Trial of Endovenous Laser Ablation of the Great Saphenous Vein 687precision of a trial with 43 as the denominator will yield
a standard error of 5.7% (pertaining to a proportion of 85%).
Analysis of the outcome was on an intention-to-treat basis.
Data from the assessments were coded, and analyses were
performed using R (version 2.10 for Windows; www.r-project.
org) and Microsoft Excel (Microsoft Redmond, Washington,
USA). The difference in primary outcome for EVLA without
ligation versus EVLA with ligation was assessed by freedom
from duplex-detected recurrence, graphically depicted by
means of KaplaneMeier curves, assuming that the event took
place exactly halfway between two follow-up visits and
difference assessed by means of the log-rank test. General-
ised linear mixed-effects modelling was used to compare
scores for VCSS over time, also taking into account the paired
nature of the randomisation of the limbs. P < 0.05 was
considered to indicate a statistically significant difference.
Results
Adetaileddescription of the2-year results has beenpublished
in our initial report.5 Of 145 patients assessed for the trial, 43
(30%) agreed to randomisation (Fig. 1). Themedian age of thepatients was 45 years (range 23e74 years). Thirty-six patients
(84%) were female and 27 (63%) had a body mass index less
than 25 kgm2. Base line characteristics of theGSV in the two
groups were not statistically significant. Incompetent
tributaries at the SFJ were detected in 2 (2.5%) of 79 visible
tributaries in the EVLAwithout SFL group and in 4 (4.8%) of 84
visible tributaries in the EVLA with SFL group. There was no
significant difference between the groups concerning the
amount of laser energy delivery (58.6 J (cm vein)1 (S.D 12.2)
in the EVLA without SFJ ligation group and 58.9 J (cm vein)1
(S.D. 12.0) in the EVLA with SFJ ligation group). At 6 weeks,
residual non-GSV varicose veins were detected in 10 limbs
(23%) in the EVLA with SFL group and in eight limbs (18.6%) in
the EVLA without SFL group. Accessory saphenous veins were
still visible in six limbs in each group. In accordance with the
protocol, all these patients requested and underwent scle-
rotherapy with Aethoxysclerol 1%.
Primary Outcome
The results of the duplex ultrasound imaging are shown in
Table 1. Five-year life table analysis (Fig. 2) showed
Table 1 Recurrent varicose veins demonstrated at Duplex ultrasound and scores for VCCS.
Baseline 6 Month (n Z 43) 1 Year (n Z 41) 2 Year (n Z 39) 5 Year (n Z 30)
Type 1a recurrence
EVLA without SFL 4 0 0 0
EVLA with SFL 0 0 0 0
Type 1b recurrence
EVLA without SFL 0 3 0 3
EVLA with SFL 0 0 0 0
Type 1c recurrence
EVLA without SFL 0 0 0 0
EVLA with SFL 0 2 3 9
Type 2a recurrence
EVLA without SFL 0 0 0 0
EVLA with SFL 0 0 0 0
Type 2b recurrence
EVLA without SFL 0 0 3 1
EVLA with SFL 1 1 3 2
SSV recurrence
EVLA without SFL 0 1 1 0
EVLA with SFL 0 0 1 0
No recurrence
EVLA without SFL 39 35 31 27
EVLA with SFL 42 39 32 21
VCSSa
EVLA without SFL 3.1 (1e5) 1.0 (0e4) 0.5 (0e2) 0.5 (0e2) 0.6 (0e2)
EVLA with SFL 3.1 (1e5) 0.9 (0e3) 0.5 (0e2) 0.5 (0e2) 0.9 (0e3)
Type 1a: incompetent great saphenous vein (GSV). Type 1b: incompetent tributaries. Type 1c: neovascularization (defined as serpentine
tributaries arising from the ligated SFJ). Type 2a: cross-groin connections. Type 2b: thigh perforators. EVLA, endovenous laser ablation.
VCSS, venous clinical severity score. SFL, saphenofemoral ligation. SSV, small saphenous vein.
a Values are mean (range).
No (of limbs) at risk 
EVLA without SFL         43       39        34               32                                                         20 
EVLA with SFL              43       43        39               34                                                         16  







Cumulative rate of freedom from groin recurrence
follow-up time since index surgery (months)
%
EVLA without SFL 
EVLA with SFL
p=  0.3552
Figure 2 KaplaneMeier life table analysis of freedom from
duplex-confirmed groin (Type 1a, 1b and 1c) varicose vein
recurrence. EVLA, endovenous laser ablation. SFL, saphenofe-
moral ligation.
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recurrence in 79% of limbs (95% confidence interval (CI);
67e92%) in the EVLA without SFL group and in 65% of limbs
(95%; CI; 51e82) of limbs in the EVLA with SFL group
(PZ 0.36). Groin varicose vein recurrence was due to neo-
vascularisation (without SVL: 0%, with SVL: 33%), re-canal-
isation (without SVL: 9%, with SVL: 0%) and incompetent
tributaries (without SVL: 14%, with SFL: 0%). The VCSS
improved significantly and was comparable in both groups.
Secondary Outcomes
In the EVLA without SFL group, 38 (88%) treated GSV
segments were ablated completely, and in the EVLA with
SFL group, 42 (98%) treated GSV segments. The differences
between the two groups were not statistically significant.
Although continuous exposure resulted in abolition of the
GSV reflux in more limbs than did intermittent exposure
(98% (45/46) vs. 88% (35/40), respectively), the differences
between the two groups were not statistically significant. In
the EVLA without SFL group, four limbs had type 1a varicose
vein recurrence and no improvement in VCSS scores,
requiring additional SFJ ligation at the 6-month follow-up.
At the 12-, 24- and 60-month follow-ups, re-canalisation of
the GSV was not observed in either group.
VCSS scores improved significantly in both groups, but
the differences between the groups were not significant
(Table 1).
Clinical Trial of Endovenous Laser Ablation of the Great Saphenous Vein 689Five-year life table analysis (Fig. 3) showed overall
freedom from varicose vein recurrence (type 1a, 1b, 1c, 2a
and 2b and small saphenous vein) in 69% of limbs (95% CI;
56e84%) in the EVLA without SFL group and in 51% of limbs
(95%; CI; 37e69%) of limbs in the EVLA with SFL group
(PZ 0.25).
Discussion
Together with the previous 2-year observation,5 this study
has shown no advantage for additional SFL, as assessed by
duplex-confirmed recurrence of varicose veins and VCSS
scores at 5 years’ follow-up. Furthermore, there appears
less neo-vascularisation after EVLA without SFL, but more
early re-canalisation and incompetent tributaries.
Endovenous procedures are performedwithout ligation of
the SFJ and tributaries. Surgical ligation of the SFJ is
considered to be a major reason for groin recurrence after
high ligation and stripping. According to van Rij et al.,3 the
rate of groin recurrence after adequate surgery is 23% of
which neo-vascularisation accounts for 85%. The notion that
neo-vascularisation in the groin after surgical treatment
leads to recurrence is supported by histological evidence.
Glass10 described healing angiogenesis induced by the groin
wound as a major source of new channels reconnecting
superficial veins to the deep femoral vein around a ligated
SFJ. Our study demonstrated neo-vascularisation in 14 limbs
(33%) after EVLA with SFL and in 0 limbs after EVLA without
SFL, at 5-year follow-up. In their prospective cohort study
comparing surgery and EVLA, Theivacumar et al.,6 detected
neo-vascularisation in 11 of 60 limbs (18%) in the surgical
group and in 1 of 69 limbs (1%) in the EVLA group, at 2 years’No (of limbs) at risk 
EVLA without SFL 43 39 33 27 14
EVLA with SFL 43 42 37 28 8







cumulative rate of freedom from overall recurrence
follow-up time since index surgery (months)
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p=  0.2543
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EVLA with SFL
Figure 3 KaplaneMeier life table analysis of freedom from
duplex-confirmed overall (Type 1a, 1b, 1c, 2a, 2b and small
saphenous vein) varicose vein recurrence. EVLA, endovenous
laser ablation. SFL, saphenofemoral ligation.follow-up.These two studies, and the5-year results of anRCT
comparing endovenous laser and surgery for great saphenous
varicose veins7 appear to show less neo-vascularisation after
EVLA without SFL. To minimise the risk of neo-vascularisa-
tion, we now avoid the use of SFL.
In the EVLA without SFJ ligation group, 16 limbs were
treated with less than 50 J (cm vein)1, of which four limbs
developed re-canalisation. As described in our initial
report, successful GSV ablation depends not only on the
mode and amount of laser energy delivered, laser wave-
length and pullback rate, but also on methodological
aspects, such as the use of perivenous infiltration, manual
compression over the vein during the procedure and a fibre
tip position 0.5e1 cm below the SFJ. Failure to occlude the
proximal GSV and/or early re-canalisation is reported in
fewer than 10% of veins after EVLA.11 It seems likely that
these patients represent primary treatment failures due to
the method of laser energy delivery. It is also possible that
these veins had temporarily occluded, but underwent early
thrombus dissolution and/or had insufficient thermal injury
to the endothelial layer of the treated vein. Further re-
canalisation of the GSV did not occur during follow-up,
a finding confirmed by others.12,13
Groin recurrence due to incompetent tributaries, such as
the anterior accessory saphenous vein, occurred in six limbs
(14%) after EVLA without SFL but in none after EVLA with
SFL. Reflux in tributaries such as the anterior accessory
saphenous vein is an important cause of recurrence.14 In this
study, we found that of 206 (80%) visible SFL tributaries at
preoperative duplex scanning, 18 (9%) had reflux in one or
more SFL tributaries; these were treated with scle-
rotherapy 6 weeks after EVLA. Competent GSV tributaries
were found in 198 limbs (77%) at duplex scanning, of which
only six (3%) resulted in recurrence. In accordance with
Theivacumar et al.,15 we believe that competent GSV
tributaries should not be treated as part of the primary
procedure because they do not have an adverse effect on
outcome 5 years after EVLA. Groin recurrence due to an
incompetent anterior accessory saphenous vein can be
treated easily with ultrasound-guided sclerotherapy,
ambulatory phlebectomy or EVLA. Intraluminal neo-vascu-
larisation after GSV ablation was not observed in this study.
Labropoulos et al.16 indentified multiple small vessels with
arterial signals, directly adjacent to the involved vein
segment, forming multiple small arteriovenous fistulae
within the obliterated vein, which may be related to the
amount of thrombus produced during EVLA and to the
intensity of inflammatory response. The absence of intra-
luminal neo-vascularisation after GSV ablation in this study
may be explained by the fact that we use manual
compression over the GSV during laser energy delivery and
so reduce the amount of thrombus formation.
In general, patients report high levels of satisfaction
following EVLA of the GSV.13 In this study, VCSS scores
show that during the first 6 months symptoms were
significantly fewer in both groups, with no difference
between groups.
In conclusion, although the rate of recurrent groin
varicosities was similar, this study shows less neo-vascu-
larisation after EVLA without SFL, but more early re-
canalisation and incompetent tributaries, at 5 years’
follow-up.
690 B.C.V.M. Disselhoff et al.Limitations
The participants and the observers in the study were obvi-
ously aware of which intervention was performed due to the
presence of a scar in the groin (lack of blinding). Second, to
reduce the risk of bias, we selected only patients with
uncomplicated C2 varicose veins and duplex-confirmed SFJ
incompetence and GSV reflux from the groin to below the
knee. Finally, during a 2-year period, 145 patients were
considered for inclusion, of which 53 participated in the
study, and, in addition, 13 patients were lost to follow-up.
More cases were considered, but a longer inclusion period or
a multicentre study was not possible at that time.
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